|
Nov 9
|
BridgeBio Pharma to Present Additional Data from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American Heart Association (AHA) Scientific Sessions 2023
|
|
Nov 4
|
Estimating The Fair Value Of BridgeBio Pharma, Inc. (NASDAQ:BBIO)
|
|
Sep 8
|
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
|
|
Sep 7
|
BridgeBio Pharma to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
|
|
Sep 6
|
BridgeBio Pharma Announces Positive Feedback from the U.S. FDA and EU EMA on the Regulatory Path for a Pivotal Phase 3 Trial of Infigratinib in Children with Achondroplasia
|
|
Aug 9
|
Wall Street Thinks BridgeBio Pharma Could Rise Over 40% -- But Will It?
|
|
Apr 27
|
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference
|